Sort by
Refine Your Search
-
Fribourg campus, with access to EPFL facilities and research infrastructure in both Fribourg and Lausanne. Additional information For more information about HOBEL: https://www.epfl.ch/labs/hobel/ For more
-
research environment Challenging projects bridging fundamental research and applied research for industry Access to cutting-edge research facilities and equipment including unique thin-film deposition
-
are encouraged to apply. We offer A stimulating and international working environment at EPFL Access to state-of-the-art micro/nanofabrication, microscopy and characterization facilities The opportunity to develop
-
candidate will be based primarily at EPFL’s Fribourg campus, with access to EPFL facilities and research infrastructure in both Fribourg and Lausanne. Additional information For more information about HOBEL
-
. The position combines Empa UESL’s expertise in developing and accessing energy system models with the methodological expertise of the IMOS Laboratory in machine learning and foundation models. Postdoctoral
-
postdoctoral position is available in the laboratory of Prof. Alex Persat (EPFL School of Life Sciences, https://www.p-lab.science/ ) to establish a new image-based drug screening platform targeting gram
-
characterization of components. Access to advanced electron microscopy and X-ray facilities is also available. We live a culture of inclusion and respect. We welcome all people who are interested in innovative
-
London, and with a strong team of postdoctoral researchers and PhD students Generous access to frontier AI models and high-performance compute for proof-assistant workloads Funded travel for collaboration
-
the earth sciences. NCCR Genesis does not aim to provide answers in all fields, but to drive innovative research and achieve decisive progress. Details on NCCR Genesis are available on its website https
-
protocols. In close collaboration with the lab of George Coukos (https://agora-cancer.ch/laboratory/coukos-lab/ ), we will derive protocols enabling rapid expansion of cancer-specific, autologous TILs